Suscripción a Biblioteca: Guest
International Journal of Medicinal Mushrooms

Publicado 12 números por año

ISSN Imprimir: 1521-9437

ISSN En Línea: 1940-4344

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 1.2 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 1.4 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.3 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00066 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.34 SJR: 0.274 SNIP: 0.41 CiteScore™:: 2.8 H-Index: 37

Indexed in

A Randomized, Placebo-Controlled, Multicenter Study of Ganoderma lucidum (W.Curt.:Fr.) Lloyd (Aphyllophoromycetideae) Polysaccharides (Ganopoly®) in Patients with Advanced Lung Cancer

Volumen 5, Edición 4, 2003, 14 pages
DOI: 10.1615/InterJMedicMush.v5.i4.40
Get accessGet access

SINOPSIS

Preclinical studies have established that the polysaccharide fractions of Ganoderma lucidum (Ling Zhi, reishi mashroom) have potential antitumor activity. Recent clinical studies have demonstrated that G. lucidum polysaccharides enhanced host immune functions (e.g., enhanced natural killer cell activity) in patients with advanced solid tumor, although objective response was not observed. A randomized double-blind, placebo-controlled, multicenter clinical trial was conducted to evaluate the efficacy and safety of the G. lucidum polysaccharides, Ganopoly®, in patients with advanced lung cancer. Sixty-eight patients with histologically confirmed advanced lung cancer were enrolled. Eligibility criteria included con. rmation of diagnosis, objective measurable disease, a Karnofsky performance score і60, life expectancy of 12 weeks or greater, no recent or concomitant anticancer therapy, and informed consent. Patients were evaluated with respect to their extent of disease and quality of life (Karnofsky score), and hematologic and selected immunological and biochemical studies at baseline and after 12 weeks of treatment with oral Ganopoly or placebo at 600 mg three times daily. Patients in both groups were similar with respect to age, sex, treatment history, and lung tumor histology. Treatment with Ganopoly gave stable disease (SD) in 13 (13/37, 35.1%) lung cancer patients at the 12-week evaluation point, which was significantly greater than that of control group (7/31, 22.6%). In 32 assessable cancer patient, treatment of Ganopoly resulted in a significant increase (>10 scores) in the KPS scores in 16 patients (50.0%); 4 patients (14.3%) obtained significant increase in the KPS scores in the control group with 29 assessable patients (p < 0.05); and 9 (28.1%) and 7 (21.9%) patients receiving Ganopoly had unchanged and reduced KPS scores, respectively. Values were 13 (46.4%) and 11 (39.3%) in the control group. Palliative effects on cancer-related symptoms such as fever, cough, weakness, sweating and insomnia have been observed in 43.8.84.4% of cancer patients receiving Ganopoly, but only a small percentage (10.7.42.9%) of cancer patients receiving placebo demonstrated improved cancer-related symptoms. Administration of Ganopoly for 12 weeks resulted in a significant (p < 0.05) increase in lymphocyte mitogenic reactivity to concanavalin A, CD3 percentage, and natural killer cell activity; a marginal increase in the CD4 percentage and CD4/CD8 ratio; but a marginal reduction of CD8. However, all these immune parameters remained unchanged or decreased in the control group. Three episodes of mild toxicity (nausea: 2; insomnia: 1) were recorded in patients receiving Ganopoly, and one episode of toxicity (vomiting) was recorded in the control group. The results indicate that Ganopoly may have an adjunct role in the treatment of patients with advanced lung cancer. Further studies are needed to explore the optimum dosing, efficacy, and safety of Ganopoly when used alone or in combination with chemotherapy/radiotherapy.

CITADO POR
  1. Cheung P. C. K., The nutritional and health benefits of mushrooms, Nutrition Bulletin, 35, 4, 2010. Crossref

  2. Yuen John W. M., Gohel Mayur Danny I., Anticancer Effects of Ganoderma lucidum: A Review of Scientific Evidence, Nutrition and Cancer, 53, 1, 2005. Crossref

  3. Jin Xingzhong, Ruiz Beguerie Julieta, Sze Daniel Man-yeun, Chan Godfrey CF, Jin Xingzhong, Ganoderma lucidum(Reishi mushroom) for cancer treatment, in Cochrane Database of Systematic Reviews, 2012. Crossref

  4. Herbal approaches to pathological states, in Principles and Practice of Phytotherapy, 2013. Crossref

  5. Kulshreshtha Shweta, Mathur Nupur, Bhatnagar Pradeep, Mushroom as a product and their role in mycoremediation, AMB Express, 4, 1, 2014. Crossref

  6. Sze Daniel M.-Y., Liu Hao, Boost Maureen V., Wong Raimond, Sagar Stephen, PHYTOTHERAPEUTICS FOR CANCER THERAPY, in Phytotherapies, 2015. Crossref

  7. Fung Shin Yee, Tan Nget Hong, Fungi as a source of antitumour agents, in Fungal Biomolecules, 2015. Crossref

  8. Pineda-Alegría Jesús Antonio, Sánchez-Vázquez José Ernesto, González-Cortazar Manases, Zamilpa Alejandro, López-Arellano María Eugenia, Cuevas-Padilla Edgar Josúe, Mendoza-de-Gives Pedro, Aguilar-Marcelino Liliana, The Edible MushroomPleurotus djamorProduces Metabolites with Lethal Activity Against the Parasitic NematodeHaemonchus contortus, Journal of Medicinal Food, 20, 12, 2017. Crossref

  9. Hsu Kai-Di, Cheng Kuan-Chen, From nutraceutical to clinical trial: frontiers in Ganoderma development, Applied Microbiology and Biotechnology, 102, 21, 2018. Crossref

  10. Wong Raimond, Sagar Stephen M., Supportive Cancer Care Using Chinese Medicine, in Supportive Cancer Care with Chinese Medicine, 2010. Crossref

  11. O’Brien Kylie, Sali Avni, Additional Therapies and Innovative Technologies, in A Clinician's Guide to Integrative Oncology, 2017. Crossref

  12. Ahmad Md Faruque, Ganoderma lucidum: A rational pharmacological approach to surmount cancer, Journal of Ethnopharmacology, 260, 2020. Crossref

  13. Jeitler Michael, Michalsen Andreas, Frings Daniela, Hübner Marisa, Fischer Moritz, Koppold-Liebscher Daniela A., Murthy Vijay, Kessler Christian S., Significance of Medicinal Mushrooms in Integrative Oncology: A Narrative Review, Frontiers in Pharmacology, 11, 2020. Crossref

  14. Jin Xingzhong, Ruiz Beguerie Julieta, Sze Daniel Man-yuen, Chan Godfrey CF, Ganoderma lucidum (Reishi mushroom) for cancer treatment, Cochrane Database of Systematic Reviews, 2019, 1, 2016. Crossref

  15. Kladar Nebojša V., Gavarić Neda S., Božin Biljana N., Ganoderma: insights into anticancer effects, European Journal of Cancer Prevention, 25, 5, 2016. Crossref

  16. Venturella Giuseppe, Ferraro Valeria, Cirlincione Fortunato, Gargano Maria Letizia, Medicinal Mushrooms: Bioactive Compounds, Use, and Clinical Trials, International Journal of Molecular Sciences, 22, 2, 2021. Crossref

  17. Zeb Mehreen, Lee Chow H., Medicinal Properties and Bioactive Compounds from Wild Mushrooms Native to North America, Molecules, 26, 2, 2021. Crossref

  18. Shetab Boushehri Maryam A., Lamprecht Alf, TLR4-Based Immunotherapeutics in Cancer: A Review of the Achievements and Shortcomings, Molecular Pharmaceutics, 15, 11, 2018. Crossref

  19. Panda Sujogya Kumar, Sahoo Gunanidhi, Swain Shasank S., Luyten Walter, Anticancer Activities of Mushrooms: A Neglected Source for Drug Discovery, Pharmaceuticals, 15, 2, 2022. Crossref

  20. Ahmad Rizwan, Riaz Muhammad, Khan Aslam, Aljamea Ahmed, Algheryafi Mohammad, Sewaket Deya, Alqathama Aljawharah, Ganoderma lucidum (Reishi) an edible mushroom; a comprehensive and critical review of its nutritional, cosmeceutical, mycochemical, pharmacological, clinical, and toxicological properties , Phytotherapy Research, 35, 11, 2021. Crossref

  21. Park Hye-Jin, Current Uses of Mushrooms in Cancer Treatment and Their Anticancer Mechanisms, International Journal of Molecular Sciences, 23, 18, 2022. Crossref

4870 Vistas de artículos 65 Descargas de artículos Métrica
4870 PUNTOS DE VISTA 65 DESCARGAS 21 Crossref CITAS Google
Scholar
CITAS

Artículos con contenido similar:

A Phase I/II Study of a Ganoderma lucidum (Curt.: Fr.) P. Karst. Extract (Ganopofy) in Patients with Advanced Cancer International Journal of Medicinal Mushrooms, Vol.4, 2002, issue 3
Guoliang Chen, Jingxian Ye, Yihuai Gao, Shufeng Zhou, Xihu Dai
Reactive Oxygen Species, Antioxidant Mechanisms, and Serum Cytokine Levels in Cancer Patients: Impact of an Antioxidant Treatment Journal of Environmental Pathology, Toxicology and Oncology, Vol.22, 2003, issue 1
Clelia Madeddu, Loredana Mura, Elena Massa, Viviana Murgia, Giulia Gramignano, Giovanni Mantovani, Maria Rita Lusso, Paolo Camboni, Luca Ferreli, Antonio Maccio
A Phase I/II Study of a Ganoderma lucidum (Curt.: Fr.) P. Karst. (Ling Zhi, Reishi Mushroom) Extract in Patients with Chronic Hepatitis В International Journal of Medicinal Mushrooms, Vol.4, 2002, issue 4
Guoliang Chen, He Gao, Jingxian Ye, Yihuai Gao, Shufeng Zhou, Xihu Dai
Immune Responses to Water-Soluble Ling Zhi Mushroom Ganoderma lucidum (W.Curt.:Fr.) P. Karst. Polysaccharides in Patients with Advanced Colorectal Cancer International Journal of Medicinal Mushrooms, Vol.7, 2005, issue 4
Guoliang Chen, He Gao, Jingxian Ye, Yihuai Gao, Min Huang, Eli Chan, Wenbo Tang, Shufeng Zhou, Xihu Dai
Chemopreventive and Tumoricidal Properties of Ling Zhi Mushroom Ganoderma lucidum (W. Curt.:Fr.) Lloyd (Aphyllophoromycetideae). Part I. Preclinical and Clinical Studies (Review) International Journal of Medicinal Mushrooms, Vol.6, 2004, issue 2
He Gao, Jin Lan, Yihuai Gao, Wenbo Tank, Shufeng Zhou
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones Precios y Políticas de Suscripcione Begell House Contáctenos Language English 中文 Русский Português German French Spain